1.38
0.07 (5.34%)
| Previous Close | 1.31 |
| Open | 1.30 |
| Volume | 39,425 |
| Avg. Volume (3M) | 114,508 |
| Market Cap | 51,601,096 |
| Price / Sales | 0.750 |
| Price / Book | 1.19 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 - 19 May 2025 |
| Profit Margin | -29.66% |
| Operating Margin (TTM) | -18.40% |
| Diluted EPS (TTM) | -0.560 |
| Quarterly Revenue Growth (YOY) | 3.60% |
| Total Debt/Equity (MRQ) | 34.17% |
| Current Ratio (MRQ) | 1.85 |
| Operating Cash Flow (TTM) | -13.58 M |
| Levered Free Cash Flow (TTM) | -10.75 M |
| Return on Assets (TTM) | -14.45% |
| Return on Equity (TTM) | -38.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Distribution (US) | Bullish | Bearish |
| Medical Distribution (Global) | Mixed | Bearish | |
| Stock | EDAP TMS S.A. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.25 |
|
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others. |
|
| Sector | Healthcare |
| Industry | Medical Distribution |
| Investment Style | Small Value |
| % Held by Institutions | 41.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Archon Capital Management Llc | 31 Dec 2024 | 982,681 |
| Bruce & Co., Inc. | 31 Dec 2024 | 553,652 |
| Cahill Financial Advisors Inc | 31 Dec 2024 | 134,960 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (HC Wainwright & Co., 1,276.81%) | Buy |
| Median | 4.50 (226.09%) | |
| Low | 2.00 (Jefferies, 44.93%) | Hold |
| Average | 8.50 (515.94%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 1.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 04 Apr 2025 | 2.00 (44.93%) | Hold | 1.61 |
| HC Wainwright & Co. | 28 Mar 2025 | 19.00 (1,276.81%) | Buy | 2.15 |
| Piper Sandler | 28 Mar 2025 | 4.50 (226.09%) | Buy | 2.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2025 | Announcement | EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting |
| 22 Apr 2025 | Announcement | EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting |
| 27 Mar 2025 | Announcement | EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results |
| 06 Mar 2025 | Announcement | EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 |
| 03 Mar 2025 | Announcement | EDAP Appoints Glen French to Board of Directors |
| 06 Feb 2025 | Announcement | Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |